世界の肺炎ワクチン市場動向

RNCOSが発行した調査報告書(RNCS50603)
◆英語タイトル:Global Pneumonia Vaccine Market Outlook 2020
◆商品コード:RNCS50603
◆発行会社(リサーチ会社):RNCOS
◆発行日:2015年6月
◆ページ数:50
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Multi-User(全社内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

According to a new research, introduction of the 10-valent pneumococcal conjugate vaccine, PCV10, decreases the rates of clinical pneumonia even in unvaccinated children, a classic example of herd immunity. With a greater number of serotypes in current vaccines, there has been more disease reduction in both vaccinated and unvaccinated populations. As vaccines evolve, similar improvements can be expected.

According to our report, “Global Pneumonia Vaccine Market Outlook 2020”, the Pneumonia vaccine market for 2014, which has been estimated at US$ 5.9 Billion, is expected to reach US$ 11 Billion by 2020, growing at a CAGR of 11.1% over the six year period. The report offers a clear and succinct take on the current Pneumococcal Vaccine Industry. The current market and future forecasts for the industry have been derived. The regional distribution of the current market has also been discussed. It has been noted that although USA and Europe are the major shareholders in the market, the developing regions are expected to account for a significant share too. This shift can be attributed to the rising incidences as well as the increasing purchasing power of the populations in these regions. Government’s focus on a preventive healthcare strategy to cut down costs is also set to play a major role in the growth of the vaccine industry.

As vaccines are highly regulated to ensure patients and users have access to safe and effective medicines, the regulatory scenarios for vaccine approval and licensing has also been discussed. It has been noted that individual governments determine which products can be marketed in their countries and many have state-regulated systems governing product pricing.

Lastly, the report discusses the three major players in the industry viz., GlaxoSmithKline, Pfizer and Merck. The competitive landscape is supplemented with a chapter highlighting the current share of every player in the market. This is followed by company profiles, wherein the general business along with key financials of every player has been provided. At the end of every profile, a strength and weakness analysis has been performed. The report provides a prudent analysis of the market and is a must have supplement for any player interested in the industry.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Pneumococcal Disease and Vaccine
4. Global Pneumonia Vaccine Market Outlook 2020
4.1 Key Geographical Markets
5. Regulatory Overview
5.1 United States
5.2 Europe
5.3 Rest of the World
5.3.1 India
5.3.2 China
5.3.3 Japan
6. Competitive Assessment
6.1 Market Share of Major Players
6.2 Company Profiles
6.2.1 GlaxoSmithKline
6.2.1.1 Business Overview
6.2.1.2 Key Financials
6.2.1.3 Strengths and Weaknesses
6.2.2 Pfizer
6.2.2.1 Business Overview
6.2.2.2 Key Financials
6.2.2.3 Strengths and Weaknesses
6.2.3 Merck
6.2.3.1 Business Overview
6.2.3.2 Key Financials
6.2.3.3 Strengths and Weaknesses

List of Figures:

Figure 4-1: Relation between Country Income and Under-5 Child Deaths from Pneumonia
Figure 4-2: Impact of Childhood Conjugate Pneumococcal Immunization on Incidence of Disease in < 5 Years of Age
Figure 4-3: Herd Immunity Impact of Childhood Pneumococcal Immunization in the US
Figure 4-4: Pneumonia Vaccine Market (Million US$), 2009-2014
Figure 4-5: Pneumonia Vaccine Market (Million Doses), 2009-2014
Figure 4-6: Pneumonia Vaccine Market (Million US$), 2014-2020
Figure 4-7: Pneumococcal Vaccine Market by Geography (%), 2014
Figure 4-8: Percentage of Adults Aged 65 and over who had ever received a Pneumococcal Vaccination: United States, 1997-2013
Figure 4-9: Age-Adjusted Death Rates for Pneumonia in 2013: United States, 1999-2013
Figure 6-1: Pneumococcal Vaccine Market Value Share by Players (%), 2014
Figure 6-2: Pneumococcal Vaccine Market Volume Share by Players (%), 2014
Figure 6-3: GSK – Revenue by Geographic Segment (%), 2014
Figure 6-4: GSK – Revenue by Business Segment (%), 2014
Figure 6-5: GSK – Break-up of Revenue of Pharmaceutical and Vaccines Business Segment (%), 2014
Figure 6-6: GSK – Synflorix Sales (Million GBP), 2010-2014
Figure 6-7: Pfizer – Revenue by Geography (%), 2014
Figure 6-8: Pfizer – Revenue by Business Segment (%), 2014
Figure 6-9: Pfizer – Prevnar Family Sales (Million USD), 2010-2014
Figure 6-10: Merck – Revenue by Business Segment (%), 2014
Figure 6-11: Merck – Revenue by Geography (%), 2014
Figure 6-12: Merck – Pneumovax 23 Sales (Million USD), 2010-2014

List of Tables:

Table 4-1: Current levels of coverage for interventions that prevent (vaccination) Pneumonia
Table 6-1: GSK – Pneumonia Vaccine Portfolio
Table 6-2: GSK – Key Financials (Million GBP), 2012-2014
Table 6-3: GSK – Strengths and Weaknesses
Table 6-4: Pfizer – Pneumonia Vaccine Portfolio
Table 6-5: Pfizer – Key Financials (Million US$), 2012-2014
Table 6-6: Pfizer – Strengths and Weaknesses
Table 6-7: Merck – Pneumonia Vaccine Portfolio
Table 6-8: Merck – Key Financials (Millions US$), 2012-2014
Table 6-9: Merck – Strengths and Weaknesses



【レポートのキーワード】

肺炎ワクチン

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の肺炎ワクチン市場動向(Global Pneumonia Vaccine Market Outlook 2020)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆